AroCell AB (AROC) - Total Liabilities
Based on the latest financial reports, AroCell AB (AROC) has total liabilities worth Skr14.01 Million SEK (≈ $1.51 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See AroCell AB working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
AroCell AB - Total Liabilities Trend (2007–2024)
This chart illustrates how AroCell AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of AroCell AB.
AroCell AB Competitors by Total Liabilities
The table below lists competitors of AroCell AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PN Poong Nyun Co. Ltd
KQ:024940
|
Korea | ₩8.21 Billion |
|
Serica Energy PLC
LSE:SQZ
|
UK | GBX1.50 Billion |
|
Terragen Holdings Ltd
AU:TGH
|
Australia | AU$1.07 Million |
|
Radius Gold Inc.
V:RDU
|
Canada | CA$546.05K |
|
Star Combo Pharma Ltd
AU:S66
|
Australia | AU$8.30 Million |
|
Mynd.ai, Inc.
NYSE MKT:MYND
|
USA | $203.97 Million |
|
Vertex Resource Group Ltd
V:VTX
|
Canada | CA$149.53 Million |
|
Future Retail Limited
NSE:FRETAIL
|
India | Rs12.21 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down AroCell AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of AroCell AB to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AroCell AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AroCell AB (2007–2024)
The table below shows the annual total liabilities of AroCell AB from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr12.93 Million ≈ $1.39 Million |
+14.96% |
| 2023-12-31 | Skr11.25 Million ≈ $1.21 Million |
-15.56% |
| 2022-12-31 | Skr13.32 Million ≈ $1.43 Million |
+33.71% |
| 2021-12-31 | Skr9.96 Million ≈ $1.07 Million |
+136.21% |
| 2020-12-31 | Skr4.22 Million ≈ $453.82K |
-61.55% |
| 2019-12-31 | Skr10.97 Million ≈ $1.18 Million |
+277.58% |
| 2018-12-31 | Skr2.90 Million ≈ $312.62K |
+2.44% |
| 2017-12-31 | Skr2.84 Million ≈ $305.18K |
-4.37% |
| 2016-12-31 | Skr2.97 Million ≈ $319.13K |
+81.72% |
| 2015-12-31 | Skr1.63 Million ≈ $175.61K |
-43.38% |
| 2014-12-31 | Skr2.88 Million ≈ $310.18K |
+26.74% |
| 2013-12-31 | Skr2.27 Million ≈ $244.74K |
+24.27% |
| 2012-12-31 | Skr1.83 Million ≈ $196.94K |
-17.52% |
| 2011-12-31 | Skr2.22 Million ≈ $238.76K |
-8.88% |
| 2010-12-31 | Skr2.43 Million ≈ $262.04K |
-18.89% |
| 2009-12-31 | Skr3.00 Million ≈ $323.06K |
+312.36% |
| 2008-12-31 | Skr728.00K ≈ $78.34K |
+31.88% |
| 2007-12-31 | Skr552.00K ≈ $59.40K |
-- |
About AroCell AB
AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB… Read more